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embryonal tumour with multilayered rosettes; FISH fluorescence in situ hybridisation; FFPE 
formalin-fixed paraffin-embedded; GOSH Great Ormond Street Hospital; HGNET high grade 
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Abstract 
Background: Our aim was to assess the added value of incorporating molecular profiling into 
routine diagnostic tumour practice. There is marked variation in the implementation of genomic 
data in tumour diagnosis, while optimal integration with conventional diagnostic technology 
remains uncertain despite several studies reporting improved diagnostic accuracy and 
selection for targeted treatments and stratification for trials. There is a need for the evaluation 
of the added value in routine clinical practice and impact on conventional, as well as 
experimental, treatments.  
 
Methods: We assessed the diagnostic and clinical utility of DNA methylation-based profiling 
in childhood central nervous system (CNS) tumours using two large national cohorts. The first 
cohort included routinely diagnosed CNS tumours in the UK (n=306) and the second was 
enriched for cases that historically have been diagnostically difficult (n=195). In the first cohort, 
we assessed how the methylation profile altered or refined diagnosis in routine clinical practice 
and estimated how this would affect standard patient management. For the research cohort, 
we determined how many cases could be solved using currently standard pathology, how 
many could only be solved using the methylation profile and how many remained unsolvable. 
 
Findings: Molecular profiling added a unique contribution to clinical diagnosis in 35% 
(107/306) of cases in routine diagnostic practice, and we estimated that it could change 
conventional management in 4% (11/306) of patients. In historically difficult to diagnose 
tumours, 51% (99/195) could be diagnosed using standard methods, with the addition of 
methylation profiling solving a further 17% (34/195) of cases. The remaining 32% (62/195) 
cases were unresolved despite specialist pathology and methylation profiling. 
 
Interpretation: Together these data provide estimates of impact that could be expected from 
routine implementation of genomic profiling into clinical practice, and also indicate limitations 
where additional techniques will be required. We conclude that DNA methylation arrays are a 
useful diagnostic adjunct for childhood CNS tumours. 
 
Funding: We are grateful for funding from the Brain Tumour Charity, Children with Cancer UK, 
Great Ormond Street Hospital Children’s Charity (INSTINCT), Olivia Hodson Cancer Fund, 
Cancer Research UK, and the National Institute of Health Research. All research at Great 
Ormond Street Hospital (GOSH) NHS Foundation Trust and UCL GOS Institute of Child Health 
is made possible by the NIHR GOSH Biomedical Research Centre.  
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Research in Context 
Evidence before this study 
The development of a CNS tumour classifier based on DNA methylation array data poses 
huge promise as a diagnostic adjunct in neuropathology. The reference dataset used to build 
the DKFZ algorithm is based on a large cohort of retrospective data and was validated using 
prospective internal and external data from multiple centres. We undertook a review of studies 
published following the description of the algorithm (using Pubmed, 2018-2019, search terms: 
methylation AND brain AND (cancer OR tumor OR tumour) AND diagnosis AND array). The 
DKFZ group published a practical implementation guideline which presents data from their 
internal cohort and a separate study focussed on the diagnostic workflow in adult brain 
tumours and how a methylation assay is performed in an adult context. The WHO does not 
yet incorporate many of the molecular CNS subtypes recognised by the community and 
methylation classifier. There is no current evidence presenting uniquely paediatric data and 
so far, no discussion of the clinical impact, while the ‘real-time’ added value of methylation 
profiling has not been addressed. 
 
Added value of this study 
We found that DNA methylation analysis added significantly to the diagnosis and treatment of 
children above and beyond specialist molecular pathology. Methylation analysis altered 
tumour subtyping in 35% of cases when used in routine practice and was predicted to change 
conventional treatment for 4% of children. Using an archival cohort, 51% of difficult to diagnose 
cases were identified without resorting to a DNA methylation profiling, which further subtyped 
17% of cases. We identified a group of cases that remain unclassifiable despite molecular 
neuropathology and methylation profiling, suggesting that novel subtypes remain to be 
identified. 
 
Implications of all the available evidence 
The data suggests that methylation profiling not only provides significant clinical impact in 
childhood brain tumours by refining diagnosis and changing treatment, but strongly suggests 
that it should be considered as a routine test in assessing such children.  
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INTRODUCTION 
Incorporation of complex molecular pathology into routine practice can improve diagnostic 
accuracy and tailored treatments, but poses significant challenges1, 2. Not only are there 
practical factors (cost, access and accreditation), but it is unclear whether we can extrapolate 
from curated research cohorts to clinical practice. In particular, genome-wide profiling studies 
have primarily taken place within research environments or as part of clinical trials3, 4. Their 
implementation in routine clinical practice is at best variable and at worst, controversial. 
 
Genomic data is of particular importance for paediatric brain tumours. Many have been 
reclassified based on their molecular profiles5-8. Also, genomic data has impact on cancer 
treatment for children, many of whom are at a high risk of death or disability depending at least 
in part on their treatment. The recent description of a methylation classifier for CNS tumours 
holds promise as an aid to diagnosis9, 10. The methylome, probably reflecting the cell of origin, 
is maintained during tumour evolution and is a stable marker of tumour type11.  
 
To reflect the differences between adult and paediatric CNS tumours, the classifier model was 
developed using a large reference cohort containing over 40% of samples from patients under 
the age of 19 years9. However, paediatric cases are under-represented in the original internal 
and external validation cohorts. 
 
Stringent study settings (such as randomised trials) can bias data by limiting inclusivity at 
recruitment. It has become clear that there is specific added value in ‘real world evidence’12, 
13. Therefore, we assessed the impact of routine methylation profiling in clinical practice and 
estimated its added value in the context of modern standard-of-care pathology using real world 
data collected during a 2 year period. We determined how often refinement of diagnosis would 
change treatment. Our experience is an exemplar of how genomic approaches can be 
assessed once translated into clinical practice. 
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Methods 
Study design and participants 
Our data includes two national cohorts: a diagnostic cohort of 306 samples to measure the 
impact on routine diagnosis and a second archival cohort encompassing 195 diagnostically 
unresolved cases (supplementary Table 1). 
 
Diagnostic Cohort: We included CNS tumours spanning a 24-month period (Sept 2016- Sept 
2018) in patients under 19 years of age, with a DNA methylation array performed in real-time 
at Great Ormond Street Hospital (GOSH) and where a consultant neuropathologist: i) 
requested the array and ii) included the data in a clinical diagnostic report. The decision to 
perform an array was at the discretion of the neuropathologist but most primary high-grade 
tumours were profiled (see results). Local and referred cases were included, with a small 
number (n=19) received from centres from outside of the UK. Cases undertaken for research 
purposes were excluded. 
 
Archival cohort: We searched for UK cases of high-grade CNS paediatric tumours (grades III 
and IV) reported between 1990 and 2018, that either failed to achieve a confident diagnosis 
at the time of initial diagnosis or fell into historical groups now recognized to represent a 
mixture of tumour groups (e.g. CNS PNETs/supratentorial PNETs). We excluded cases with 
an initial histological diagnosis of medulloblastoma, glioblastoma, ependymoma, AT/RT, 
Ewing’s sarcoma, teratoma and sarcoma as these were beyond the study’s scope.  
Ethical approval: clinical cohort approval was given by Great Ormond Street NHS Foundation 
Trust as service evaluation (Registration No. 2301). The archival cohort was analysed under 
ethical approval granted by BRAIN UK tissue bank (REC: 14/SC/0098, References 16/007 
and 17/007)  
Procedures 
Methylation profiling: DNA was extracted from 50 µm formalin-fixed paraffin-embedded 
(FFPE) tissue taken either as 5x10 µm rolls or macrodissected sections to enrich for tumour 
content. DNA was extracted using the Promega Maxwell 16 FFPE Tissue LEV DNA 
Purification Kit and quantified using a Nanodrop, before bisulphite conversion of up to 500 ng 
DNA, using the Zymo EZ DNA Methylation-Gold kit. Bisulphite converted FFPE DNA was 
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treated with the Illumina Infinium FFPE DNA Restore kit. DNA was assayed using Illumina 
Infinium MethylationEPIC BeadChip arrays processed by UCL Genomics, according to the 
Infinium HD FFPE Methylation Assay automated protocol (Illumina). 
 
Methylation classification: methylation data was imported into R v3.5.3 using minfi14 
(version 1.22.1) and normalised with the included function preprocessIllumina. Missing CpG 
beta values were imputed using the impute.knn function implemented in the impute package15. 
A DNA methylation classification model (MNP v11b2, current at the time of implementation) 
was used (www.molecularneuropathology.org/mnp) 9. This resulted in an output indicating the 
best match of tumour diagnosis and a corresponding calibrated score9, ranging from 0-1.  
 
Reporting methylation outputs: during the period of clinical implementation, if the classifier’s 
predicted output gave a calibrated score ≥0·9, the methylation class was used in the clinical 
report in keeping with previous publications9. When scores were <0·9, the classifier was 
deemed to be of uncertain significance and was not included in the clinical report10. All outputs 
were considered alongside standard neuropathology16, 17 and when relevant, further testing 
was performed to confirm the result.  
 
Copy number (CN) plots were generated from methylation data using Conumee18. During the 
study timeframe study, CN plots were not routinely reported clinically. We retrospectively 
reviewed the plots to identify diagnostically relevant changes in specific tumour types. Gains 
and losses were called when probe intensity was ±0·15 on log2 scale and amplifications were 
called when >0·619, 20. 
 
The rationale for undertaking methylation analysis in clinical cases was categorised as: (i) 
tumours that were difficult to diagnose, (ii) rare tumour types requiring further confirmation, (iii) 
cases where the purpose of the array was to determine the subtype of a tumour and (iv) cases 
with limited available diagnostic material. 
 
The diagnostic impact of the predicted methylation class in clinical cases was reviewed by a 
single observer (JCP) independently of the reporting pathologist, and categorised as (i) 
classification that confirmed the final diagnosis but did not add additional information, (ii) 
classification that confirmed and refined the final diagnosis, providing additional molecular 
subtyping not available by histopathology alone, (iii) classification that amended the initial 
diagnosis, leading to a change in final diagnosis, (iv) classifications of uncertain significance 
and (v) classifications considered potentially misleading.  
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Methylation data from the clinical cohort that modified the final diagnosis were assessed by a 
senior paediatric neuro-oncologist (DH) to determine if the data would indicate a change in 
therapeutic strategy according to relevant national guidance for childhood tumours in the UK 
at the time of diagnosis. We considered methylation data to have had a clinical impact when 
the patient’s treatment would have differed if the data had not been available. The same 
oncologist identified cases where the methylation data could in the future help to triage 
patients for forthcoming trials; such as targeted therapies or improved risk stratification. We 
analysed this latter data separately as it is more subjective. 
 
Review of archival cohort: an immunohistochemical panel was performed on the cases from 
the archival cohort, including GFAP, synaptophysin, Ki-67, NeuN, OLIG2, INI-1, SMARCA4, 
LIN28A, mutant H3K27M, H3K27 trimethylation, CD56, CD99, EMA, p65/RELA and L1-CAM 
21. FFPE sections were cut at 3 µm and automated staining performed on a Leica BOND-MAX. 
The histopathology was reviewed by a paediatric neuropathologist (TSJ) to determine if a 
confident diagnosis could be offered on the basis of the neuropathological features. DNA 
methylation arrays and the classifier algorithm were performed as described above using MNP 
v2 and v4. Where appropriate, cytogenetic testing (fluorescence in-situ hybridisation, FISH) 
and confirmation of suspected mutations (sequencing, RT-PCR) was performed.  
 
Mapping samples against reference cohorts: sample methylation data were read into R using 
Minfi and preprocessed using the included preprocessIllumina function. Beta values were 
extracted and matched against those in the MNP reference cohort dataset (v4)9. These 
combined data were used to generate t-SNE plots containing both reference and GOSH 
cohorts for manual inspection of clustering in cases where GOSH samples could not be 
robustly classified by the MNP algorithm. Research samples whose co-ordinates were within 
or directly adjacent to methylation reference subgroups were considered to belong to the 
respective tumour subgroup. 
 
Statistical analysis 
Confidence intervals of 95% were calculated in R using the prop.test function from the stats 
package. Statistical testing was undertaken in SPSS (IBM version 24), significance set to 
≤0·01. Pairwise correlations of continuous data were tested using Spearman’s rank test, while 
pairwise comparisons of population variance were tested using the Kruskal-Wallis test.  
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Role of the funding source 
The funder had no role in the study design, data collection, analysis and interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study and 
had final responsibility for the decision to submit for publication.  
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Results 
Implementation of methylation profiling in routine clinical practice 
To determine the impact of molecular testing on diagnostic yield, we reviewed the GOSH 
experience of methylation profiling in childhood CNS tumours. For the period under 
consideration, standard-of-care involved morphology, immunohistochemistry for standard 
diagnostic markers, FISH and single gene analysis (Sanger sequencing and qPCR)17. During 
the two-year period studied, we diagnosed 484 brain tumours in patients under 19 years of 
age. The estimated brain tumour incidence in this age group is 633 cases per year22 in the 
UK. Therefore, this cohort is approximately 40% of the nation’s childhood CNS tumours 
(242/633, total national population of 66 million23). We undertook diagnostic DNA methylation 
arrays in 306 cases or 63% of our total cases; the equivalent of 24% of the population’s 
childhood brain tumours (Figure 1A). 
 
Clinical cases (n=306) were those that were referred by a neuropathologist for diagnosis 
(Figure S1). Most high-grade tumours were profiled (Figure 1B). We categorised cases 
according to the primary indication for profiling (Figure S2): 162 cases were requested 
specifically to establish a tumour subtype (53%) e.g. medulloblastoma; 115 cases were 
undertaken as they were diagnostically difficult cases (38%); 19 were undertaken where the 
diagnosis was certain but the tumour type was considered unusual in the age group (6%); and 
ten were undertaken to improve diagnostic certainty when the biopsy was small (3%).  
Diagnostic yield of real-world methylation profiling 
The principal outcome from the arrays was classification using an algorithm from the German 
Cancer Research Centre (DKFZ)9. In keeping with previous publications9, 10, a calibrated score 
greater than 0·9 indicates successful classification (see below for analysis of scores <0·9). 
From the entire diagnostic cohort (irrespective of DNA quality), 49% (149/306) cases gave a 
calibrated score of 0·9 or greater. Diagnostic impact was assessed by reviewing the reports 
to determine what effect the array had on the real-time diagnosis (Figure 2) 9, 24. Overall, we 
report a total recall rate of 48% (146/306), and a precision rate at n (calibrated scores >0·9) 
of 98% (146/149). 
 
Cases where the array confirmed but did not refine the final diagnosis accounted for 26% 
(39/149) of classifying cases or 13% (39/306) of all cases (Figure 2). Diagnoses in this group 
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mostly belonged to CNS tumours with molecular subgroups that were identifiable by existing 
diagnostic tests e.g. WNT-activated medulloblastoma. 
 
Array predictions that both confirmed and refined the final diagnosis by providing additional 
molecular subtyping data, not otherwise available by existing histopathological or molecular 
evaluation, accounted for 64% (99/149) of the classifying cases or 32% (99/306) of all cases 
(Figure 2). Many of these tumours were those where an array was then used as the primary 
method of subtyping, e.g. some subtypes of medulloblastoma and high-grade glioma. 
 
There were five array predictions that led to an amended final diagnosis (Supplementary 
table 2A), including two newly recognized tumours, high grade neuroepithelial tumour 
(HGNET) with MN1 alteration and HGNET with BCOR alteration 25.  
 
In three cases, the array made a prediction that was considered potentially significant, but that 
could not be confirmed, and we regarded these results as of uncertain significance 
(Supplementary table 2B). 
 
In no case was the array entirely misleading if taken in the context of other radiological and 
pathological data. We only considered 3 array predictions to be potentially misleading if 
interpreted in isolation (Supplementary table 2C) but the clinical management was not likely 
to have changed. The first case was an embryonal tumour that classified as a pineoblastoma 
however, on review there was no radiological involvement of the pineal gland. It is possible 
that this is a limitation of the radiology rather than the array, or it may represent an ectopic 
origin for pineoblastoma10. In the remaining two cases, the array predicted control brain tissue 
but the result was disregarded as there was morphological evidence of tumour. The 
corresponding sections were reviewed and the prediction was explainable because of low 
tumour content.  
 
Factors that affected diagnostic yield 
To explore the factors that affected the score, we reviewed potential confounding factors 
including technical factors, clinical indication, patient age and diagnosis. 
 
All cases were processed irrespective of the DNA quality. Therefore, to analyse the impact of 
technical factors, we compared the percentage of failed probes to the calibrated score. As 
expected, we found a negative correlation between probe failure rate (PFR) and calibrated 
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score (ρ=-0·39, p<0·0001 figure S3). Next we binned cases into four groups based on PFR 
(Figure 3A). No cases with a PFR over 5% and few over 2% gave a calibrated score over 0·9. 
However, there remained significant number of non-classifying cases with low PFRs 
suggesting DNA quality only accounts for a proportion of the unclassified cases. 
 
We hypothesised that the classifier results may vary in different clinical contexts. To address 
this, we analysed the calibrated score based on the patient’s age, site of preparation, final 
diagnosis and the clinical indication for the array. We found no correlation between age and 
calibrated score (p=0.75) suggesting that the classifier worked equally well across all ages of 
children and young adults (Figure S3). However, the calibrated score varied according to the 
indication for undertaking an array (p<0·0001, Figure 3B). The highest scores were from cases 
undertaken for sub-typing or confirmation of confident diagnoses. Intermediate scores were 
observed when the arrays were undertaken to solve diagnostically challenging cases whilst 
the lowest scores came from cases with small biopsies. This suggests that the expected 
success of methylation analysis depends on the clinical question being addressed.  
 
To determine if the performance of the classifier differed in different tumour types, we 
considered how the calibrated scores varied according to the final diagnosis (p<0·0001, 
Figure 3C). The tumour type with the highest success rate was medulloblastoma in which 59 
of the 79 cases profiled (75%) produced a confident subtype. Ependymoma had more modest 
results, where 15 of the 29 cases (52%) classified. Notably most RELA-altered ependymomas 
(7 out of 9 cases) successfully classified by array. 
 
Fifty-nine patients were diagnosed with a high-grade astrocytoma (grades III and IV) and of 
these, 41% (n=24) were classifiable (Figure 3C). However, the rate was higher in specific 
subtypes e.g. diffuse midline gliomas with a histone H3K27 mutation had confident scores in 
7 out of 10 cases and G34 mutated glioblastomas had confident scores in all 4 cases. 
Methylation data increased grade to glioblastoma in 10 high-grade astrocytomas. 
 
In low-grade glioma or glioneuronal tumours, a calibrated score ≥0·9 was assigned in only 
33% of cases (28/85), compared to our cohort’s average of 49% (Figure 3C). This suggests 
that this tumour group is particularly challenging to classify by this technique. 
Copy number data 
Inferred copy number (CN) data generated from methylation arrays were not included in the 
clinical reports during the time of this study. However, to assess the potential of CN data, we 
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retrospectively compared the CN results to existing diagnostic data (i.e. FISH) in 
medulloblastoma and embryonal tumours with multilayered rosettes (ETMR).  
 
MYC and MYCN amplification are poor prognostic factors in medulloblastoma26. Both FISH 
and CN plots were available for 62 out of 79 reported medulloblastomas, with a total of 
12 patients reported to have either MYC (n=6) or MYCN (n=7) amplification by FISH (one 
patient had the unusual combination of both) (Figure 4 and S4). The CN plots had a specificity 
of 100% for both MYC and MYCN amplification compared to FISH. The sensitivity of the array 
was only 67% for MYC and 57% for MYCN compared to FISH. It is likely that the low sensitivity 
is due to the difficulty in detecting focal amplifications by bulk DNA techniques. 
  
We assessed amplification of the microRNA cluster on chromosome 19 (C19MC) that defines 
C19MC-altered ETMRs. In all four ETMRs, C19MC amplification was detected by both FISH 
and by array CN plot analysis (data not shown). 
 
MGMT promoter methylation assessment in paediatric cases 
MGMT promoter methylation is considered of prognostic relevance in adult gliomas and 
associated with sensitivity to alkylating chemotherapy (temozolomide) 27 but its value in 
childhood cancers remains unconfirmed28, 29, 30, 31. We found that MGMT promoter methylation 
was rare in children and mostly restricted to small subsets of tumour types (see supplementary 
material). 
 
Impact on therapy 
We reviewed all cases where the methylation array modified the diagnosis to determine if the 
additional data would have implications for treatment according to standard protocols used in 
the UK. In 11 patients, the diagnostic modification would have mandated a change in 
management based on current protocols (supplementary Table 4). To estimate the potential 
impact of these changes, we expressed this as a percentage of all arrays performed 
(irrespective of technical failures), finding that 4% (CI +/-2%) of cases (11/306) would have an 
impact on standard management. 
 
We also estimated which might predict treatment changes that could be offered in the next 
few years in trials. When considering these patients, a future change in therapy was possible 
for 6% of cases (18/306); bringing the total estimated upper limit on future therapeutic impact 
to 10% (CI +/-3%) of cases tested.  
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Impact of suboptimal classification scores 
At the time of the diagnosis, only scores ≥0·9 were reported in our clinical practice. However 
lower scores have been suggested to be useful when used with caution10 and are reported at 
other centres24. As these outputs were not used for real-time diagnosis, we categorised them 
according to how the classifier’s prediction related to the final diagnosis (Figure 5A). The lower 
the calibrated score, the greater the risk of a misleading result (Fig. 5B and C). We conclude 
that cases with low calibrated scores should be considered with caution, and used alongside 
other testing. 
The impact of methylation profiling in diagnostically challenging cases 
The data in the first cohort estimates the impact of methylation profiling in routine clinical 
practice. The data suggests it is successful in well-defined entities but shows variable results 
where the diagnosis was uncertain. To explore this, we determined the impact on tumours that 
have defied diagnosis. We hypothesised that a proportion of such tumours might be 
diagnosable by current pathological criteria without advanced molecular technology, while 
others may be solved by methylation profiling and finally, some may remain unresolved 
despite contemporary histology and molecular analysis. 
 
We collated a national cohort of archival high-grade brain tumours that either failed to achieve 
a confident diagnosis at the time of the initial diagnosis or fell into groups that are now 
recognised to represent a mixed group of molecular entities (e.g. CNS PNETs/supratentorial 
PNETs). Cases with sufficient tissue (n=195) were subjected to a standardised 
immunohistochemistry panel and the histological features were reviewed by a 
neuropathologist (TSJ). 
 
Based on the histopathology, we made a confident diagnosis (i.e. cases where the 
immunohistochemistry gave an unambiguous results e.g. INI1 loss in AT/RT) in 51% of the 
research cohort (99/195), suggesting that many cases can be resolved without further 
molecular testing (Figure 6A and B). In 17% (34/195) we were able to achieve a confident 
diagnosis using methylation profiling in combination with histology (Figure 6A and C). The 
remaining 32% of cases (62/195) could not be confidently resolved using the array or 
histopathology. 15 of these cases were explained by technical problems (12 cases had high 
PFRs and three had low tumour content). A single case (an infantile hemispheric glioma (IHG)) 
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was resolved by the latest version of the methylation classifier (mnp.v4). We suggest that the 
remaining 46 unsolvable cases are a combination of novel entities, tumour predisposition 
syndromes9, and cases where the technology is not optimal for their identification (Figure 6A). 
 
To test this, we plotted the unsolved samples against the original DKFZ reference cohort 
(Figure 6D). On t-SNE plot, we assessed the proximity of unsolvable cases to known 
methylation classes. We estimate that only 35% (16/46) of the unsolvable cases are examples 
of known entities, already part of the existing methylation classifier, and the remainder may 
be novel entities. 
 
We noted a handful of unsolved cases clustered near but separately from the reference cases 
(Figure 6D). These cases may be rare variants of known CNS tumours, for example ETMR-
like tumours with DICER1 mutations32 or potentially novel, undescribed CNS tumour entities. 
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Discussion 
Using two national cohorts of paediatric CNS tumours, we have evaluated the impact and 
limitations of incorporating DNA methylation arrays into routine diagnostic practice. We found 
that methylation profiling alters the diagnosis in 35% (CI +/-5%) of cases and affects treatment 
in 4% (CI +/-2%) of patients. 
 
We have been conservative in measuring the added value of these techniques beyond 
standard-of-care testing17 and considered changes in patient management according to 
current protocols. We assessed all arrays including those that failed, not preselecting the best 
quality samples, as we wished to determine how the arrays performed based on real clinical 
samples. We suggest that these are acceptable approaches for measuring the realistic clinical 
impact of molecular profiling on clinical practice, avoiding unrealistic expectations from 
clinicians.  
 
The data nonetheless supports routine use of methylation profiling for childhood CNS tumours. 
Although the numbers may appear low, considering the debilitating long-term impact of 
treatment on the developing brain and the poor prognosis of many childhood brain tumours, 
changing treatment in as few as 3-4% of children is likely to be highly significant. This would 
equate to 23 children annually in the UK22, 274 in Europe and 120 in the United States33. 
Based on this data, and contrary to adult practice24, we use methylation profiling in all CNS 
parenchymal tumours, where there is sufficient tissue and tumour content.  
 
Classification rates vary depending on the clinical cohort to which the classifier is applied. The 
DKFZ validation cohorts reported variable classification rates across 5 external centres (no 
tumour match in 5-42% of cases, average 22%)9. One adult study reported 44% of tested CNS 
tumours were unclassifiable using a calibrated threshold of 0·8424. In our paediatric cohort, we 
observed a significant proportion of unclassified cases (51%), possibly explained by the 
frequent complex diagnostic cases seen in childhood neuropathology.  
 
Our data suggest that as well as technical factors, clinical ones such as the clinical question 
and the tumour type are important predictors of the classifier’s performance. This is important 
as the a priori likelihood of a meaningful prediction depends on the question being asked. For 
example, if the purpose is to subtype medulloblastoma, we would expect a high success rate. 
If in contrast, an array is used to solve a difficult case that has defied conventional diagnostic 
approaches, it is less likely to succeed. In the second cohort, we included cases that had 
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historically defied diagnosis or had diagnoses that were historical (e.g. supratentorial PNET). 
We were able to offer a confident diagnosis in 51% of cases using histological techniques 
alone without an array. In part, this reflects an increased recognition of specific entities (e.g. 
diffuse midline glioma, H3K27 mutant) and the availability of more specific markers (e.g. 
antibodies against mutant H3K27). However, it emphasises that new diagnostic techniques 
should not be directly compared to historical diagnoses.  
 
The second cohort also identified tumours that we were unable to diagnose with pathology or 
methylation profiling. Although it is not certain what factors account for these ‘un-diagnosable’ 
cases, we consider that they are either novel entities or recognised tumour types where 
current technology cannot diagnose them. The latter may be due to technical factors (such as 
low tumour content) or intrinsic limitations of the diagnostic methods. However, based on the 
clustering of the cases (Figure 6), we estimate that only 35% of these ‘un-diagnosable’ cases 
are recognised entities. This gives an upper limit to the number of cases that are potentially 
novel (65%) and these warrant further investigation.  
 
Access to specialist pathology varies globally (both molecular and histological expertise) and 
that the impact of methylation arrays on diagnosis might reflect this. We speculate the impact 
of methylation profiling might be greater in non-specialist centres, although the frequency of 
complex cases may be reduced. Additionally, as novel immunohistochemical markers are 
identified, the impact of profiling may change. For example, H3K27me3 was recently 
introduced to discriminate ependymoma PFA from PFB34. Had this been implemented at the 
time, the overall diagnostic impact of the arrays would have changed from 35% to 34% 
(107/306 and 103/306) with no change in treatment impact. 
 
Subgrouping of some tumours may currently have minimal clinical impact (e.g. within pilocytic 
astrocytoma), however evidence for risk stratification will only become clear once sufficient 
outcome data is linked to molecular subtyping. Identification of targetable driver mutations 
(e.g. BRAF and NTRK) is largely dependent on sequencing data that methylation profiling 
cannot explicitly provide; in our experience classification can help triage genetic testing and in 
the future we expect this to increase as more experimental treatments are made available. 
 
Finally, we compared inferred copy number data to standard FISH testing. We conclude that 
for some indications, methylation profiling could replace FISH (e.g. C19MC in ETMR). It may 
also be helpful to identify diagnostically relevant chromosomal changes (e.g. CDKN2A/B loss 
in PXA or monosomy chr6 in medulloblastoma, data not presented) or to indicate fusion 
events10. However, we caution against absolute replacement for traditional testing because of 
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the effects of tumour heterogeneity or low tumour content. The danger of missing prognostic 
information by CN alone is highlighted by the limited sensitivity for MYC and MYCN 
amplification in medulloblastoma. 
 
The limitation of our study arises from the nature of the cohorts. While the clinical cohort 
captures very many of the UK’s children’s brain tumours, there may be sampling biases e.g. 
possible enrichment for difficult to diagnose tumours or those requiring molecular data for full 
subtyping. The research cohort is limited to high-grade tumours, and we have not explored a 
retrospective study of low-grade tumours. It will be useful to continue to review the impact 
when all tumours are routinely profiled. 
 
We have used methylation profiling of childhood brain tumours to develop an approach to 
assess the impact of genomic technology in clinical practice. This real-world evidence 
approach complements those of traditional controlled prospective studies. We suggest that 
this is a general approach that allows new genomic technology to be. Also established 
techniques could be assessed using these criteria; how much of the established 
immunohistochemistry would show similar clinical impact if tested in the same way? 
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Figure Legends 
Figure 1. Routine implementation of DNA methylation arrays into a specialist paediatric 
neuropathology centre. (A) Annual proportion of UK’s cases reported with and without a 
DNA methylation array (EPIC, 850K) at our neuropathology centre. Annual UK incidence 
(n=633) based on CRUK data22. Values plotted are on an annual basis, i.e. Total number of 
cases in the cohort are halved. Values at the top of each plotted bar are the sum of cases by 
age. (Total cases reported = 484, total cases with an array = 306). (B) Proportions of arrays 
performed in all cases reported during two years with a final diagnosis of medulloblastoma, 
ependymoma, low- and high-grade gliomas.  
 
Figure 2. DNA methylation classification has additive diagnostic value in 35% ±5% of 
CNS paediatric cases (n=107). Graphical representation of the overall impact of arrays on 
routine diagnostic practice for paediatric CNS tumours. We considered an array to have 
additive value when the output refined (99) or amended (5) the diagnosis or added other 
relevant diagnostic data, of uncertain significance (3). 
 
Figure 3. Diagnostic yield of DNA methylation arrays is highest in well characterised 
CNS tumours. Calibrated scores for cases were broken down (A) by binned probe failure rate 
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(PFR), (B) by indication for array and (C) by broad diagnosis. The red dotted lines in B and C 
represent the 0.9 calibrated threshold, values equal and above this value were accepted for 
diagnostic reporting. The numbers are sample numbers; the heavy black line is the median, 
the boxes are the interquartile range and the whiskers are the range excluding outliers. 
Outliers are plotted as circles (if 1.5-3.0x box length form the box edge) and asterisks (if more 
than 3.0x box length form the box edge). 
 
Figure 4. Accuracy of inferring amplification data from DNA methylation array data. 
Amplification data inferred from CN plot The Brain Tumour Charity was compared to the 
results of reported cytogenetic data (FISH), for 62 medulloblastoma patients. (A) Sensitivity 
and specificity calculations for MYCN and (B) MYC. For example, CN plots and example 
cytogenetic imaging, see supplementary figure S4. 
 
Figure 5. Impact of suboptimal scoring predictions on the final reported diagnosis. (A) 
One in every 3 suboptimal scoring predictions (range 0 to <0·9) will be misleading (or 35%, 
55/157). (B) Precision of classifier predictions broken down by calibrated score range. 
Calculated by the sum of outputs that matched the final diagnosis and were plausible but 
unconfirmed, divided by the total number of cases. For scores 0·7 - 0·9, 1 in every 14 
predictions is estimated to be misleading; compared to scores above 0·9 where only 1 in every 
50 predictions was misleading (C) Median calibrated score by diagnostic impact. 
 
Figure 6. Modern pathology in combination with DNA methylation profiling can assign 
a final diagnosis to 68% of difficult to diagnose cases. (A) Review of 195 archival cases 
using current neuropathology practices and how the diagnosis was reached. Insert represents 
62 undiagnosable cases which were further analysed. (B) Breakdown of cases diagnosed by 
local standard pathology methods without requiring array data (n=99) and (C) cases reviewed 
that required pathology and array data for a molecular diagnosis (n=34). (D) t-SNE plot of 47 
remaining unsolvable cases passing QC which failed to classify (black) overlaid on the DKFZ 
reference cohort of known CNS tumour subgroups (coloured points). Samples that clustered 
within or adjacent to known groups were considered to match to the corresponding molecular 
subgroup. Abbreviations: HGG: high grade glioma, LGG: low grade glioma, PXA: pleomorphic 
xanthoastrocytoma, GNT: glioneuronal tumour, MB: medulloblastoma, ETMR: embryonal 
tumour with multilayered rosettes, ATRT: atypical teratoid/rhabdoid tumour, NB: 
neuroblastoma, HGNET: high grade neuroepithelial tumour, NOS: not otherwise specified; 
GBM G34: glioblastoma IDH wildtype H3.3 G34 mutant; GBM RTK I: glioblastoma IDH 
wildtype subclass RTK I; GBM RTK II: glioblastoma IDH wildtype subclass RTK II; GBM 
RTK III: glioblastoma IDH wildtype subclass RTK III; GBM MYCN: glioblastoma IDH wildtype 
 22 
subclass MYCN; GBM MES: glioblastoma IDH wildtype subclass mesenchymal; GBM MID: 
glioblastoma IDH wildtype subclass midline; MB, G3: Medulloblastoma, subclass group 3; MB, 
G4: Medulloblastoma, subclass group 4; ETMR: embryonal tumour with multilayered rosettes.  
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